Payment overview · 2025
General Payments
$329.37
16 reported records · 10 companies
Healthcare provider profile · identity verified
Jonathan Dychko
Allopathic & Osteopathic Physicians|Internal Medicine · SUN CITY CENTER, FL · NPI 1063972420
Verified facts
What the public records show
CMS Open Payments records show Jonathan Dychko received $329.37 in general payments during 2025 across 16 reported records.
PFIZER INC. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 207 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $84.59 | 25.7% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $43.16 | 13.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $41.70 | 12.7% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $33.92 | 10.3% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $33.73 | 10.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.32 | 6.2% | 1 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $20.32 | 6.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.20 | 5.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $17.82 | 5.4% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $15.61 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $329.37 | 16 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $55.97 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $55.97 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $43.16 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $41.70 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $33.73 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.62 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.58 | 1 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.32 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $18.20 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $15.76 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 207 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 119 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
35 | 32 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
76 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
119 | 35 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
207 | 58 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 640 | 208 |
| Levothyroxine Sodium | Levothyroxine Sodium | 563 | 168 |
| Amlodipine Besylate | Amlodipine Besylate | 456 | 150 |
| Losartan Potassium | Losartan Potassium | 323 | 113 |
| Lisinopril | Lisinopril | 292 | 100 |
| Metoprolol Succinate | Metoprolol Succinate | 289 | 100 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 240 | 87 |
| Methylprednisolone | Methylprednisolone | 235 | 190 |
| Omeprazole | Omeprazole | 219 | 79 |
| Eliquis | Apixaban | 207 | 58 |
| Gabapentin | Gabapentin | 188 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 66 |
| Metformin Hcl | Metformin Hcl | 183 | 62 |
| Trazodone Hcl | Trazodone Hcl | 180 | 66 |
| Valsartan | Valsartan | 169 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 167 | 66 |
| Simvastatin | Simvastatin | 162 | 51 |
| Alprazolam | Alprazolam | 158 | 65 |
| Montelukast Sodium | Montelukast Sodium | 145 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 47 |
| Ozempic | Semaglutide | 119 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 41 |
| Carvedilol | Carvedilol | 115 | 36 |
| Furosemide | Furosemide | 111 | 55 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 108 | 44 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 34 |
| Famotidine | Famotidine | 104 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 100 | 34 |
| Zolpidem Tartrate | Zolpidem Tartrate | 98 | 31 |
| Sertraline Hcl | Sertraline Hcl | 95 | 34 |
| Meloxicam | Meloxicam | 93 | 37 |
| Finasteride | Finasteride | 89 | 30 |
| Allopurinol | Allopurinol | 86 | 30 |
| Azithromycin | Azithromycin | 86 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 31 |
| Synthroid | Levothyroxine Sodium | 81 | 24 |
| Tramadol Hcl | Tramadol Hcl | 81 | 38 |
| Donepezil Hcl | Donepezil Hcl | 80 | 22 |
| Potassium Chloride | Potassium Chloride | 79 | 27 |
| Glimepiride | Glimepiride | 76 | 27 |
| Jardiance | Empagliflozin | 76 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 43 |
| Bupropion Xl | Bupropion Hcl | 74 | 28 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 68 | 63 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 67 | 21 |
| Nifedipine Er | Nifedipine | 67 | 20 |
| Alendronate Sodium | Alendronate Sodium | 66 | 22 |
| Bumetanide | Bumetanide | 65 | 17 |
| Clonazepam | Clonazepam | 65 | 16 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 65 | 27 |
| Spironolactone | Spironolactone | 64 | 24 |
| Glipizide | Glipizide | 63 | 20 |
| Memantine Hcl | Memantine Hcl | 63 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 59 | 28 |
| Warfarin Sodium | Warfarin Sodium | 57 | 12 |
| Entresto | Sacubitril/Valsartan | 56 | suppressed |
| Mirtazapine | Mirtazapine | 56 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 55 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 52 | 45 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 17 |
| Atenolol | Atenolol | 50 | 20 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 50 | 47 |
| Lorazepam | Lorazepam | 49 | 20 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 44 | 20 |
| Lovastatin | Lovastatin | 41 | 15 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 40 | 35 |
| Levemir Flexpen | Insulin Detemir | 40 | suppressed |
| Prednisone | Prednisone | 40 | 24 |
| Pregabalin | Pregabalin | 40 | 14 |
| Metformin Hcl Er | Metformin Hcl | 39 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | 20 |
| Topiramate | Topiramate | 38 | suppressed |
| Tradjenta | Linagliptin | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 37 | 12 |
| Celecoxib | Celecoxib | 37 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | 12 |
| Ezetimibe | Ezetimibe | 36 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 36 | 11 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 35 | 32 |
| Irbesartan | Irbesartan | 34 | 11 |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 32 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Baclofen | Baclofen | 31 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 30 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Nystatin | Nystatin | 27 | 18 |
| Brilinta | Ticagrelor | 26 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 26 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Aripiprazole | Aripiprazole | 25 | 14 |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ketoconazole | Ketoconazole | 25 | 12 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 20 |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 21 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 21 | 12 |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Diazepam | Diazepam | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Ondansetron Odt | Ondansetron | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Estradiol | Estradiol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Procrit | Epoetin Alfa | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $329.37 · 16 records | PFIZER INC. | AUSTEDO XR, ELIQUIS, EVENITY, FFRct, GEMTESA, KISUNLA, MOUNJARO, NURTEC ODT, Ozempic, REXULTI, Rybelsus, TRELEGY ELLIPTA, ZAVZPRET, ZENPEP, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error